Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

  • End date
    Dec 31, 2021
  • participants needed
  • sponsor
    Fudan University
Updated on 22 January 2021


This is a single arm, open-label Phase II clinical trial to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients with metastatic pancreatic cancer.


While GT (Gemcitabine + Nab-paclitaxel) is one of the preferred regimens for metastatic pancreatic cancer, we have yet to determine the optimum number of cycles for GT treatment regimen. In this single arm, open-label clinical trial, metastatic pancreatic cancer patients will be received nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) and gemcitabine 1000 mg/m^2 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel therapeutic.

The safety and efficacy of each group will be assessed through ORR, PFS, OS and adverse effects as graded by CTC-AE 5.0.

Condition Metastatic Pancreatic Cancer
Treatment Gemcitabine, Paclitaxel for Injection(Albumin Bound)
Clinical Study IdentifierNCT03929094
SponsorFudan University
Last Modified on22 January 2021


Yes No Not Sure

Inclusion Criteria

Signed informed content obtained prior to treatment. The patients were fully explained and understood the purpose, contents, predicted efficacy, pharmacological effects, and risks of this study
target population
the patients were confirmed as metastatic pancreatic cancer by histopathology or cytopathology
At least one measurable objective lesion (both primary and metastatic) was identified based on the RECIST1.1 criteria
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
The expected survival after surgery 3 months
The subjects have good compliance, can be treated and followed up, and voluntarily comply with the relevant provisions of this study
No contraindications for gemcitabine and nab-paclitaxel
Age and reproductive status
Age 18 years and 75 years
Subjects of child-bearing age must agree to take effective contraceptive measures during the study period; Serum or urine pregnancy tests must be negative for women of childbearing age 24 hours before the start of chemotherapy
Women must not lactate

Exclusion Criteria

The target disease has cerebral metastasis
medical history and complications
patients had uncontrolled serious medical condition that the investigator considered may affect the subject's to receive treatment under the study program, For example, patients with severe medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc
Dementia, changing of mental state or any mental illness which could hinder understanding or informed consent or fill out questionnaires
History of allergy or hypersensitivity to any therapeutic ingredient
Combined with other malignant tumors excepted pancreatic cancer within the first 5 years of randomization, excepted well-treated basal cell or squamous cell carcinoma of the skin, localized prostate cancer after radical resection, and ductal carcinoma in situ of the breast after radical resection
Previously received systemic therapy for advanced/metastatic pancreatic cancer
Subjects who had previously been pathologically diagnosed with squamous cell carcinoma (no organ limitation) and received neoadjuvant/adjuvant therapy with taxa regimen
Patients who had Grade 2 or above Peripheral neuropathy
Abnormal results of physical examination and laboratory examination
Absolute neutrophil count (ANC) 90g/L 1.5 109/L; Platelets (PLT) 90g/L 100 109/L; Hemoglobin (Hgb) < 90g/L
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]/ alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) >2.5 institutional upper limit of normal (ULN), >5 institutional upper limit of normal (ULN) (hepatic metastases); Total bilirubin (TBIL)>1.5 ULN
Creatinine (CRE)> 1.5 ULN
Prothrombin time (PT) and international normalized ratio (INR) > 1.5 ULN. Unless the subject had received anticoagulant treatment
Subjects had hepatitis b surface antigen (HBsAg)-positive and hbv-dna titer in peripheral blood greater than or equal to 1000 copy number /L;If HBsAg is positive and the peripheral blood hbv-dna <1000 copy number /L, the subjects will be eligible for inclusion if the investigator considers that chronic hepatitis b is stable and does not increase the risk of subjects
Human immunodeficiency virus (HIV)- or hepatitis C virus (HCV) positive patients
Patients combined with other anti-tumor drugs
Participation in any trial drug treatment or another interventional clinical trial 30 days before screening period
The researchers considered that there were other conditions that were not suitable for enrollment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note